Unisex vs sex-specific estimated fetal weight charts for fetal growth monitoring: a population-based study.

estimated fetal weight fetal growth restriction neonatal morbidity sex-specific charts small-for-gestational-age unisex charts

Journal

American journal of obstetrics & gynecology MFM
ISSN: 2589-9333
Titre abrégé: Am J Obstet Gynecol MFM
Pays: United States
ID NLM: 101746609

Informations de publication

Date de publication:
01 2022
Historique:
received: 20 09 2021
revised: 22 10 2021
accepted: 02 11 2021
pubmed: 12 11 2021
medline: 1 2 2022
entrez: 11 11 2021
Statut: ppublish

Résumé

In contrast with birthweight or other growth charts, a feature of most intrauterine charts is that they are not differentiated by sex. Differences in weight by sex during pregnancy are considered to be relatively minor; however, small systematic differences may affect the sensitivity and specificity of screening for fetuses with growth restriction. To assess differences between unisex and sex-specific estimated fetal weight charts at the third-trimester ultrasound with regard to the sex ratio of fetuses detected with an estimated fetal weight <10th percentile and subsequent detection of small-for-gestational-age newborns with morbidity at birth. The study included 9940 singleton live births from a French population-based study in 2016. Main outcomes were an estimated fetal weight <10th percentile at the routine third-trimester ultrasound between 30 and 35 weeks of gestation, and small for gestational age infants (birthweight <10th percentile) with neonatal morbidity (Apgar score <7 at 5 minutes and/or resuscitation in delivery room and/or admission to a neonatal unit). We used 2 charts with unisex and sex-specific options: the World Health Organization international standard chart and a customized chart for fetal sex based on Gardosi's gestation-related optimal weight model adapted to the French population (Epopé). Hadlock's unisex chart, commonly used in clinical care and research, was also included to provide an external reference. We compared the proportions of female and male fetuses with an estimated fetal weight <10th percentile and the sensitivity and specificity of such estimated fetal weight for predicting small-for-gestational-age newborns with morbidity when using unisex vs sex-specific charts, overall and by sex. Among all singleton births, there were 51.6% males and 48.4% females. Males faced higher risks of being small-for-gestational-age with morbidity at birth (2.4% vs 1.8%; P=.031). Using the World Health Organization unisex chart, 6.9% of males and 9.9% of females had an estimated fetal weight <10th percentile vs 9.9% of males and 7.1% of females with the sex-specific chart; these proportions were 3.5% and 4.6% and 4.3% and 2.7%, respectively, for the Epopé. Proportions of estimated fetal weight <10th percentile using Hadlock's chart were slightly higher than those obtained using the unisex World Health Organization chart (7.5% of males and 10.6% of females), but the difference of about 3% was the same. The sensitivity of an estimated fetal weight <10th percentile for identifying small-for-gestational-age newborns with morbidity differed for males and females by type of chart; unisex charts detected more small-for-gestational-age females with morbidity and sex-specific charts detected more small-for-gestational-age males with morbidity, but the overall sensitivity was the same (49.1% for the World Health Organization chart and Hadlock's chart and 34.9% for the Epopé chart). This study suggests that the use of sex-specific charts instead of unisex charts would reduce sex bias in intrauterine growth screening during the third trimester of pregnancy. Prospective studies are needed to assess the effects of using sex-specific charts rather than unisex charts on obstetrical management and outcomes.

Sections du résumé

BACKGROUND
In contrast with birthweight or other growth charts, a feature of most intrauterine charts is that they are not differentiated by sex. Differences in weight by sex during pregnancy are considered to be relatively minor; however, small systematic differences may affect the sensitivity and specificity of screening for fetuses with growth restriction.
OBJECTIVE
To assess differences between unisex and sex-specific estimated fetal weight charts at the third-trimester ultrasound with regard to the sex ratio of fetuses detected with an estimated fetal weight <10th percentile and subsequent detection of small-for-gestational-age newborns with morbidity at birth.
STUDY DESIGN
The study included 9940 singleton live births from a French population-based study in 2016. Main outcomes were an estimated fetal weight <10th percentile at the routine third-trimester ultrasound between 30 and 35 weeks of gestation, and small for gestational age infants (birthweight <10th percentile) with neonatal morbidity (Apgar score <7 at 5 minutes and/or resuscitation in delivery room and/or admission to a neonatal unit). We used 2 charts with unisex and sex-specific options: the World Health Organization international standard chart and a customized chart for fetal sex based on Gardosi's gestation-related optimal weight model adapted to the French population (Epopé). Hadlock's unisex chart, commonly used in clinical care and research, was also included to provide an external reference. We compared the proportions of female and male fetuses with an estimated fetal weight <10th percentile and the sensitivity and specificity of such estimated fetal weight for predicting small-for-gestational-age newborns with morbidity when using unisex vs sex-specific charts, overall and by sex.
RESULTS
Among all singleton births, there were 51.6% males and 48.4% females. Males faced higher risks of being small-for-gestational-age with morbidity at birth (2.4% vs 1.8%; P=.031). Using the World Health Organization unisex chart, 6.9% of males and 9.9% of females had an estimated fetal weight <10th percentile vs 9.9% of males and 7.1% of females with the sex-specific chart; these proportions were 3.5% and 4.6% and 4.3% and 2.7%, respectively, for the Epopé. Proportions of estimated fetal weight <10th percentile using Hadlock's chart were slightly higher than those obtained using the unisex World Health Organization chart (7.5% of males and 10.6% of females), but the difference of about 3% was the same. The sensitivity of an estimated fetal weight <10th percentile for identifying small-for-gestational-age newborns with morbidity differed for males and females by type of chart; unisex charts detected more small-for-gestational-age females with morbidity and sex-specific charts detected more small-for-gestational-age males with morbidity, but the overall sensitivity was the same (49.1% for the World Health Organization chart and Hadlock's chart and 34.9% for the Epopé chart).
CONCLUSION
This study suggests that the use of sex-specific charts instead of unisex charts would reduce sex bias in intrauterine growth screening during the third trimester of pregnancy. Prospective studies are needed to assess the effects of using sex-specific charts rather than unisex charts on obstetrical management and outcomes.

Identifiants

pubmed: 34763120
pii: S2589-9333(21)00223-8
doi: 10.1016/j.ajogmf.2021.100527
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

100527

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Auteurs

Isabelle Monier (I)

Obstetrical, Perinatal and Pediatric Epidemiology Research Team, Université de Paris, Center for Research on Epidemiology and Statistics, Institut national de la santé et de la recherche médicale, Institut national de la recherche agronomique, Paris, France (Dr Monier, Ms Hocquette, and Drs Blondel, Goffinet, and Zeitlin); Department of Obstetrics and Gynaecology, Antoine Béclère Hospital, Assistance Publique-Hôpitaux de Paris, University Paris Saclay, Clamart, France (Drs Monier and Benachi). Electronic address: isabelle.monier@inserm.fr.

Anne Ego (A)

The French National Centre for Scientific Research, Public Health Department CHU Grenoble Alpes, Grenoble INP Institute of Engineering and Management, Grenoble Alpes University, TIMC-IMAG, Grenoble, France (Dr Ego); Les centres d'investigation clinique U1406, Institut national de la santé et de la recherche médicale, Grenoble, France (Dr Ego).

Alexandra Benachi (A)

Department of Obstetrics and Gynaecology, Antoine Béclère Hospital, Assistance Publique-Hôpitaux de Paris, University Paris Saclay, Clamart, France (Drs Monier and Benachi).

Alice Hocquette (A)

Obstetrical, Perinatal and Pediatric Epidemiology Research Team, Université de Paris, Center for Research on Epidemiology and Statistics, Institut national de la santé et de la recherche médicale, Institut national de la recherche agronomique, Paris, France (Dr Monier, Ms Hocquette, and Drs Blondel, Goffinet, and Zeitlin).

Béatrice Blondel (B)

Obstetrical, Perinatal and Pediatric Epidemiology Research Team, Université de Paris, Center for Research on Epidemiology and Statistics, Institut national de la santé et de la recherche médicale, Institut national de la recherche agronomique, Paris, France (Dr Monier, Ms Hocquette, and Drs Blondel, Goffinet, and Zeitlin).

François Goffinet (F)

Obstetrical, Perinatal and Pediatric Epidemiology Research Team, Université de Paris, Center for Research on Epidemiology and Statistics, Institut national de la santé et de la recherche médicale, Institut national de la recherche agronomique, Paris, France (Dr Monier, Ms Hocquette, and Drs Blondel, Goffinet, and Zeitlin); Maternité Port-Royal, Assistance Publique-Hôpitaux de Paris, APHP Centre-Université de Paris, FHU PREMA, Paris, France (Dr Goffinet).

Jennifer Zeitlin (J)

Obstetrical, Perinatal and Pediatric Epidemiology Research Team, Université de Paris, Center for Research on Epidemiology and Statistics, Institut national de la santé et de la recherche médicale, Institut national de la recherche agronomique, Paris, France (Dr Monier, Ms Hocquette, and Drs Blondel, Goffinet, and Zeitlin).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH